약물 스크리닝 시장 규모, 점유율, 동향 분석 리포트 : 제품 유형별, 샘플 유형별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Drug Screening Market Size, Share & Trends Analysis Report By Product Type (Instruments, Rapid Testing Devices), By Sample Type (Urine Sample, Breath Sample), By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,194,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,571,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,325,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

약물 스크리닝 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 약물 스크리닝 시장 규모는 2030년까지 119억 9,000만 달러에 달할 것으로 예측되며, 예측 기간 중 CAGR 4.0%로 성장하고 있습니다.

직장 안전에 대한 관심 증가, 규제에 대한 대응, 검사 방법의 기술적 진보에 힘입어 약물 남용에 대한 정확한 탐지 요건이 이 시장을 주도하고 있습니다.

영국에서 약물 및 알코올 서비스를 이용하는 성인의 수가 2020-2021년 275,896명에서 2021-2022년 289,215명으로 4.8% 증가하며 영국내 약물 남용이 확산되고 있음을 보여주고 있습니다. 약물 남용 유병률 증가는 증거 기반 치료 옵션에 대한 접근성 확대, 약물 및 알코올 남용의 위험에 대한 인식을 높이기 위한 공중보건 캠페인 등 효과적인 예방 및 치료 전략의 필요성을 더욱 강조하고 있습니다.

또한 2020년 12세 이상 미국인의 불법 약물 사용률은 약 3,731만 명으로 지난 수년간 전년 대비 3.8% 증가했으며, 이러한 증가 추세는 시장 성장의 중요한 원동력이 되고 있습니다. 이러한 증가는 직장, 학교 및 의료 환경에서 종합적인 약물 검진 프로그램이 시급히 필요함을 강조하고, 안전, 규제 준수 및 약물 남용으로 고통받는 사람들에게 적절한 치료와 지원을 제공해야 한다는 점을 강조합니다.

또한 신제품 출시, 합병, 인수 등 시장 기업의 구상이 시장 성장에 기여하고 있습니다. 예를 들어 2024년 2월, 뉴욕의 선도적인 약물 검사 프로바이더인 Mobile Health는 고용주를 위해 1시간 이내에 결과를 얻을 수 있는 신속한 약물 검사를 도입했습니다. 정확하고 다용도한 소변 기반 검사에 초점을 맞춘 이 혁신은 채택 프로세스를 앞당기고 뉴욕의 인재 확보에 혁명을 일으켰습니다. 또한 2023년 12월에는 유전자 마커를 통해 개인의 오피오이드 사용 장애 발병 위험을 평가하는 AvertD 검사가 FDA의 승인을 받아 오피오이드 위기 대응에 있으며, 중요한 혁신이 될 것으로 예상됩니다. 오피오이드 진통제를 처음 복용하기 전, 특히 수술을 앞두고 있는 환자에게 사용하도록 설계되었습니다. 이 검사는 환자와 의료진이 오피오이드 사용에 대한 정보에 입각한 의사결정을 내릴 수 있도록 도와 중독과 오남용의 위험을 줄이는 것을 목표로 하고 있습니다.

AvertD의 승인은 2022년 8월 FDA 과다복용 방지 프레임워크 도입, 2023년 3월과 7월 비처방 나록손 비강용 비강용제 승인 등 오피오이드 위기에 대응하기 위한 FDA의 광범위한 노력의 일환입니다. 이러한 위기 대응에 대한 FDA의 노력은 오피오이드 사용 장애의 위험을 평가하고 완화하는 데 도움이 되는 의료기기 개발에 대한 지속적인 지원에서도 확인할 수 있습니다.

약물 스크리닝 시장 보고서 하이라이트

• 제품 유형별로는 소모품이 2023년 가장 빠른 매출로 시장 점유율을 차지할 것으로 예상되며, 주요 기업이 키트 개발을 위한 광범위한 조사 개발 구상로 인해 예측 기간 중 가장 빠른 성장률로 성장할 것으로 예상됩니다.
• 유형별로는 소변 샘플이 2023년 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다. 소변을 통한 약물 검사는 일반적으로 모발 검사와 같은 다른 검사 방법에 비해 비용 효율적입니다.
• 약물 치료 센터의 최종 용도 분야가 2023년 시장을 장악했는데, 이는 약물 남용 치료 및 재활에 대한 관심이 높아지면서 이러한 센터의 약물 검사 서비스에 대한 수요가 증가했기 때문입니다.
• 북미는 첨단화된 의료 인프라, 불법 약물 소비량, 직장내 약물 검사 필요성 등의 요인으로 인해 세계 시장을 독점하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 약물 스크리닝 시장 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 억제요인 분석
• 약물 스크리닝 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석
  • 가격 분석

제4장 약물 스크리닝 시장 : 제품 유형 추정·동향 분석

• 세계의 약물 스크리닝 시장 : 제품 유형 대시보드
• 세계의 약물 스크리닝 시장 : 제품 유형의 변동 분석
• 세계의 약물 스크리닝 시장 : 제품 유형, 매출별
• 기기
• 신속 검사 기기
• 소모품
• 서비스 및 기타

제5장 약물 스크리닝 시장 : 기술 추정·동향 분석

• 세계의 약물 스크리닝 시장 : 샘플 유형 대시보드
• 세계의 약물 스크리닝 시장 : 샘플 유형의 변동 분석
• 세계의 약물 스크리닝 시장 : 샘플 유형별, 매출별
• 뇨샘플
• 호기 샘플
• 구강액 샘플
• 모발 샘플
• 기타 샘플

제6장 약물 스크리닝 시장 : 최종 용도 추정·동향 분석

• 세계의 약물 스크리닝 시장 : 최종 용도 대시보드
• 세계의 약물 스크리닝 시장 : 최종 용도 변동 분석
• 세계의 약물 스크리닝 시장 : 최종 용도별, 매출별
• 병원
• 형사사법 및 법집행기관
• 직장
• 약물 치료 센터
• 개인 사용자
• 통증 관리 센터
• 학교와 대학
• 기타

제7장 약물 스크리닝 시장 : 제품 유형, 샘플 유형, 최종 용도별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 주요 시장 참여 기업별 최근 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 구도
  • 주요 유통업체와 채널 파트너 리스트
  • 주요 고객
  • 주요 시장의 기업 점유율 분석, 2023년
  • Abbott
  • Quest Diagnostics Incorporated
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Siemens Healthcare AG
  • Laboratory Corporation of America Holdings
  • Alfa Scientific Designs, Inc.,
  • OraSure Technologies, Inc.
  • Omega Laboratories, Inc.
  • Dragerwerk AG &Co. KGaA
  • Bio-Rad Laboratories, Inc.

KSA

영문 목차

영문목차

Drug Screening Market Growth & Trends:

The global drug screening market size is anticipated to reach USD 11.99 billion by 2030 and is growing at a CAGR of 4.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by increasing workplace safety concerns, regulatory compliance, and requirement for accurate detection of substance abuse, aided by technological advancements in testing methods.

The increase in number of adults in contact with drug and alcohol services in England has increased from 275,896 in 2020 - 2021￢ to 289,215 in 2021 - 2022, representing a 4.8% rise, which signifies a growing prevalence of substance abuse in the country. The rising prevalence of substance abuse further propels the need for effective prevention and treatment strategies, including the expansion of access to evidence-based treatment options and public health campaigns to raise awareness about the risks of drug and alcohol misuse.

Similarly, the incidence of illegal substance use among Americans aged 12 and older in 2020 was around 37.31 million, and shows a 3.8% year-over-year increase over the years; this rising prevalence serves as a significant driver for the market. This increase highlights the urgent need for comprehensive drug screening programs in workplaces, schools, and healthcare settings to ensure safety, compliance with regulations, and provision of appropriate care and support for individuals struggling with substance abuse.

Furthermore, initiatives by market players such as new product launches, mergers, acquisitions, and others contribute to market growth. For instance, in February 2024, Mobile Health, the leading drug testing provider in NYC, introduced rapid drug testing for employers, ensuring results in an hour or less. With a focus on urine-based testing for accuracy and versatility, this innovation advances the hiring process, revolutionizing talent acquisition in NYC. In addition, in December 2023, the FDA's approval of the AvertD test, which assesses an individual's risk of developing opioid use disorder through genetic markers, marks a significant innovation in the fight against the opioid crisis. This test, developed by AutoGenomics, Inc., is designed to be used before a patient is first exposed to oral opioid pain medications, particularly in patients scheduled for surgical procedures. The test is intended to help patients and healthcare providers make informed decisions about opioid use, potentially reducing the risk of addiction and misuse.

The approval of AvertD is part of FDA's broader efforts to address opioid crisis, which includes the introduction of FDA Overdose Prevention Framework in August 2022 and the approval of nonprescription naloxone nasal spray products in March and July 2023. The FDA's commitment to addressing these crisis is evident in its continued support for the development of medical devices that can help assess and mitigate the risk of opioid use disorder.

Drug Screening Market Report Highlights:

• Consumables dominated the product type segment with the fastest revenue market share in 2023 and is anticipated to grow at fastest growth rate over the forecast period owing to extensive R&D initiatives undertaken by major players to develop kits
• Based on type segment, urine sample dominated the market with the largest revenue share in 2023 attributed to the ease of collection. Urine drug testing is generally more cost-effective compared to other testing methods, such as hair testing
• Drug treatment centers end-use segment dominated the market in 2023, attributed to the increasing focus on substance abuse treatment and rehabilitation, leading to a higher demand for drug testing services in these centers
• North America dominated the global market owing to factors such as advanced healthcare infrastructure, the region's high consumption of illegal substances, and the necessity for workplace drug tests

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Sample Type
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product type outlook
  • 2.2.2. Sample type outlook
  • 2.2.3. End-use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Drug Screening Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing drug and alcohol consumption
    • 3.2.1.2. Growing demand for drug screening measures
    • 3.2.1.3. Rise in government funding
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Rising false positive and negative results in drug screeni9ng limits screening process
    • 3.2.2.2. Rise in privacy concerns limiting the expansion of drug screening practices
• 3.3. Drug Screening Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Drug Screening Market: Product Type Estimates & Trend Analysis

• 4.1. Global Drug Screening Market: Product Type Dashboard
• 4.2. Global Drug Screening Market: Product Type Movement Analysis
• 4.3. Global Drug Screening Market by Product Type, Revenue
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. Immunoassays Analyzers
    • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. Chromatography Instruments
    • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.4. Breath Analyzer
    • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4.2. Fuel Cell Breath Analyzer
    • 4.4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4.3. Semi-conductor Breath Analyzer
    • 4.4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4.4. Others Breath Analyzer
    • 4.4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Rapid Testing Devices
  • 4.5.1. Rapid testing devices market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.2. Urine Testing Devices
    • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.2. Drug Testing Cups
    • 4.5.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.3. Dip Cards
    • 4.5.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.4. Drug Testing Cassettes
    • 4.5.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.3. Oral Fluid Testing Devices
    • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Consumables
  • 4.6.1. Consumables market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.2. Assay Kits
    • 4.6.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.3. Sample Collection Devices
    • 4.6.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.4. Calibrators & Controls
    • 4.6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.5. Other Consumables
    • 4.6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Services and Others
  • 4.7.1. Services and others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Drug Screening Market: Technology Estimates & Trend Analysis

• 5.1. Global Drug Screening Market: Sample Type Dashboard
• 5.2. Global Drug Screening Market: Sample Type Movement Analysis
• 5.3. Global Drug Screening Market by Sample Type, Revenue
• 5.4. Urine Samples
  • 5.4.1. Urine samples market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Breath Samples
  • 5.5.1. Breath samples market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Oral Fluid Samples
  • 5.6.1. Oral fluid samples market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Hair Samples
  • 5.7.1. Hair samples market estimates and forecasts 2018 - 2030 (USD Million)
• 5.8. Other Samples
  • 5.8.1. Other samples market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Drug Screening Market: End-use Estimates & Trend Analysis

• 6.1. Global Drug Screening Market: End-use Dashboard
• 6.2. Global Drug Screening Market: End-use Movement Analysis
• 6.3. Global Drug Screening Market by End-use, Revenue
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Criminal Justice & Law Enforcement Agencies
  • 6.5.1. Clinical laboratories market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Workplaces
  • 6.6.1. Workplaces market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. Drug Treatment Centers
  • 6.7.1. Drug treatment centers market estimates and forecasts 2018 - 2030 (USD Million)
• 6.8. Individual Users
  • 6.8.1. Individual users market estimates and forecasts 2018 - 2030 (USD Million)
• 6.9. Pain Management Centers
  • 6.9.1. Pain management centers market estimates and forecasts 2018 - 2030 (USD Million)
• 6.10. Schools & Colleges
  • 6.10.1. Schools & Colleges market estimates and forecasts 2018 - 2030 (USD Million)
• 6.11. Others
  • 6.11.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Drug Screening Market: Regional Estimates & Trend Analysis by Product Type, Sample Type, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.6. Denmark
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.8. Norway
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Abbott
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Quest Diagnostics Incorporated
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. F. Hoffmann-La Roche Ltd
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Thermo Fisher Scientific Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Siemens Healthcare AG
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Laboratory Corporation of America Holdings
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Alfa Scientific Designs, Inc.,
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. OraSure Technologies, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Omega Laboratories, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Dragerwerk AG & Co. KGaA
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Bio-Rad Laboratories, Inc.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives

관련자료